The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention

• Published in: Cancer research (Chicago, Ill.) Vol. 81; no. 9; pp. 2259 - 2269
• Main Authors: Khan, Tashbib, Kryza, Thomas, Lyons, Nicholas J, He, Yaowu, Hooper, John D
• Format: Journal Article
• Language: English
• Published: United States 01.05.2021
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.can-20-2978

CUB-domain containing protein 1 (CDCP1) is a type I transmembrane glycoprotein that is upregulated in malignancies of the breast, lung, colorectum, ovary, kidney, liver, pancreas, and hematopoietic system. Here, we discuss CDCP1 as an important hub for oncogenic signaling and its key roles in malignant transformation and summarize approaches focused on exploiting it for cancer diagnosis and therapy. Elevated levels of CDCP1 are associated with progressive disease and markedly poorer survival. Predominantly located on the cell surface, CDCP1 lies at the nexus of key tumorigenic and metastatic signaling cascades, including the SRC/PKCδ, PI3K/AKT, WNT, and RAS/ERK axes, the oxidative pentose phosphate pathway, and fatty acid oxidation, making important functional contributions to cancer cell survival and growth, metastasis, and treatment resistance. These findings have stimulated the development of agents that target CDCP1 for detection and treatment of a range of cancers, and results from preclinical models suggest that these approaches could be efficacious and have manageable toxicity profiles.